Provider review
WellMedr Review: It Mixes a GLP-1 With NAD+ and Sells It for Focus
WellMedr sells the usual compounded GLP-1s, and then something this site has not seen anywhere else: a GLP-1 mixed into the same injection as NAD+ and vitamin B12, marketed for the brain. "Energy & Focus+" is compounded tirzepatide "formulated with NAD+ and Vitamin B12" and sold for enhanced cognitive and physical output — a combination no registered trial has tested.
WellMedr's core business is an ordinary compounded GLP-1 operation with modest claims, a published $99 starting price and a phone number you can actually ring. What makes it worth a review on this site is the product beside it. "Energy & Focus+" is compounded tirzepatide mixed into one injection with NAD+ and vitamin B12 and sold for "enhanced cognitive and physical output" — a combination no registered trial has tested, in which one component has a large phase 3 program that never measured cognition and another has no completed human trial at all. "Muscle & Energy+" goes further, stacking a microdose, an oral route, four ingredients and an explicitly non-weight-loss indication onto the same molecule. Nothing on the site addresses whether a multi-ingredient sterile injection is stable or potent in each part, no pharmacy is named, and no certificate exists. Alongside that: the core compounded products never name the molecule outside their URL, two incompatible lifetime discounts run on one page, and the four-week shipping cycle quietly turns "$99 a month" into thirteen charges a year.
Worth trusting if
- You want a phone line you can ring, because WellMedr publishes a staffed number and an email address on its own site.
- You expect to titrate upward, because both compounded plans say the price is the same whatever the dose.
- You want no minimum term, because "cancel or change anytime" sits on both compounded plans and no term is published anywhere.
Be skeptical if
- You budget by the calendar month, because the plan WellMedr calls a one-month supply is billed every 21 days.
- You want the molecule named on the product, because its core plans say "Compounded GLP-1/GIP" and only the web address says tirzepatide.
- You are drawn to Energy & Focus+, because no trial has tested a GLP-1 mixed with NAD+ and B12 for cognitive output.
Approved + compounded
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.wellmedr.com. A link is not a recommendation to take anything.
Provenance
What WellMedr actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Ozempic® (brand, cash-pay) — $1,399 a month for Ozempic and $1,599 for Zepbound, month-to-month — several times the manufacturers' published direct self-pay prices for the same products.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Energy & Focus+ (compounded tirzepatide with NAD+ and B12) — No price is rendered on the product page and the Shopify variant returns $0.00. It does not appear after the eligibility quiz either — the quiz is followed by a shipping-address form, and the figure only exists in the checkout, which charges $129 every 21 days. The weight-loss page advertises this line "Starting At $99 a month", "Shipped every 4 weeks"; the shipping cadence is 4 weeks and the billing cadence is 3.
- Energy & Focus+ (compounded semaglutide with NAD+ and B12) — Not rendered on the product page, and not after the eligibility quiz either — the only figure is in the checkout, on a 21-day billing cycle.
- Muscle & Energy+ (oral microdose GLP-1/GIP) — Not rendered on the product page, and not after the eligibility quiz either — the only figure is in the checkout, on a 21-day billing cycle.
- Compounded GLP-1/GIP (handle: injectable-tirzepatide) — "Monthly Plan Starting At $99 a month… Tirzepatide shipped every 4 weeks." The shipping cadence is not the billing cadence: the checkout charges $129 every 21 DAYS, which is 17.33 charges a year and $2,236 — not the $1,287 a four-week reading gives, and not the $1,188 the headline implies.
- Compounded GLP-1 (handle: injectable-semaglutide) — Priced within the same plan structure. Shipped every four weeks but BILLED every 21 days, and no figure appears anywhere before the checkout.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
3
Molecules with human evidence
For the use they are sold for, out of 6 products reviewed here. The evidence belongs to the molecule, not to WellMedr.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from WellMedr’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Energy & Focus+ (compounded tirzepatide with NAD+ and B12)Tirzepatide with NAD+ and vitamin B12 · Compounded (503A)No trial supports this claim
“Compounded Tirzepatide injection formulated with NAD+ and Vitamin B12 to help support balanced focus, sustained energy, and metabolic performance. Designed for individuals seeking enhanced cognitive and physical output through GLP-1/GIP–based therapy.”
Read on the WellMedr site, August 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no registered trial of tirzepatide co-formulated or co-administered with NAD+, in any phase, for any endpoint. Each part fails separately as well: injected NAD+ has no completed randomized human trial supporting a restoration-of-function claim and no registered study reporting a COGNITIVE endpoint by any route, and the tirzepatide program (SURMOUNT) measured weight and cardiometabolic outcomes, never cognition or focus. The searches themselves work — run in the same pass, tirzepatide alone returns 158 registry records naming it as an intervention.
This is a combination product sold for an indication neither of its active components has been tested for. Tirzepatide has a large phase 3 program, and every trial in it measured weight, glycemia or cardiovascular outcomes — not focus, not cognition, not "cognitive output". Injected NAD+ has no completed randomized human trial at all, and no registered study of it reports a cognitive endpoint by any route. And no trial has tested the two together, in one syringe or otherwise. So "designed for individuals seeking enhanced cognitive and physical output" describes an intention rather than a demonstrated effect, and the word "formulated" carries an implication of deliberate pharmacological design that nothing published supports. B12 is the one component with a real cognitive story, and it is a narrow one: correcting a B12 DEFICIENCY can improve cognition. That is not a reason to give B12 to someone who is not deficient, and the page does not raise the distinction.1,2
Energy & Focus+ (compounded semaglutide with NAD+ and B12)Semaglutide with NAD+ and vitamin B12 · Compounded (503A)No trial supports this claim
“Compounded Semaglutide injection formulated with NAD+ and Vitamin B12 to help support balanced energy, focus, and metabolic performance. Designed for individuals seeking sustained mental and physical vitality alongside GLP-1 benefits.”
Read on the WellMedr site, August 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no registered trial of semaglutide co-formulated or co-administered with NAD+, in any phase, for any endpoint. Separately, injected NAD+ has no completed randomized human trial supporting a restoration-of-function claim and none reporting a cognitive endpoint, and the semaglutide program — STEP for weight, SUSTAIN for glycemia, SELECT for cardiovascular outcomes — reported none of "energy", "focus" or "mental vitality" as an endpoint.
The same combination logic with the other molecule, and the same gap. "Sustained mental and physical vitality alongside GLP-1 benefits" pairs an unevidenced claim with an evidenced one in a single phrase: the GLP-1 benefits are real and well documented for weight and glycemia, and the mental vitality is not documented at all. Putting them in the same sentence lets the established half carry the unestablished one. No trial has tested semaglutide with NAD+, and no trial of either reports a cognitive or energy endpoint.1,3
Muscle & Energy+ (oral microdose GLP-1/GIP)Tirzepatide with NAD+, L-carnitine and vitamin B12 · Compounded (503A)No trial supports this claim
“Compounded oral microdose GLP-1/GIP* (contains Tirzepatide), formulated with NAD+, L-Carnitine, and Vitamin B12 to help support energy, focus, and metabolic performance—without a primary weight-loss emphasis.”
Read on the WellMedr site, August 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no completed trial of a sub-therapeutic "microdose" tirzepatide regimen against any endpoint, no registered trial of an ORAL compounded tirzepatide preparation, and no trial of tirzepatide combined with NAD+, L-carnitine or B12. Four separate things are unstudied here — the dose, the route, the combination and the indication — and no registered study of any of them exists.
This product stacks four unevidenced choices on one molecule. The DOSE is a deliberate microdose, and no completed trial has tested a sub-therapeutic tirzepatide regimen against any endpoint. The ROUTE is oral, and no registered trial has tested a compounded oral tirzepatide. The COMBINATION adds NAD+, L-carnitine and B12, none of which has been studied with tirzepatide. And the INDICATION is explicitly not weight loss — "without a primary weight-loss emphasis" — which is the only thing tirzepatide has ever been trialled for. To WellMedr's credit the description does name the molecule, unlike its core compounded line, and the asterisk on "GLP-1/GIP*" signals that a qualification exists.2
Compounded GLP-1/GIP (handle: injectable-tirzepatide)Tirzepatide · Compounded (503A)Claim matches the trials
“Clinically guided treatment designed to regulate appetite, enhance metabolism, and support lasting weight management—all through convenient online care. Includes: Licensed provider review and ongoing medical oversight. Medical Weight-Care Coach for guidance and progress support. Tailored dosage adjustments based on your individual response.”
Read on the WellMedr site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide at the highest tolerated dose over 72 weeks, with lifestyle intervention in every arm.
Nothing here outruns the trials: appetite regulation and weight management are exactly what tirzepatide has been shown to do, no percentage is quoted and no trial is name-dropped. "Enhance metabolism" is the loosest phrase and is defensible as shorthand for the metabolic effects that were measured. The problem with this product is not the claim but the label: the title says "Compounded GLP-1/GIP" and the description never names the molecule. A buyer only learns it is tirzepatide from the URL slug, `injectable-tirzepatide`. WellMedr names the molecule plainly for its branded products ("Contains Tirzepatide") and for its combination products, so the omission is specific to the core compounded line.2
Compounded GLP-1 (handle: injectable-semaglutide)Semaglutide · Compounded (503A)Claim matches the trials
“A once-weekly injectable treatment designed to help regulate appetite, balance blood sugar, and support long-term weight management—all through convenient online care.”
Read on the WellMedr site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks. No compounded semaglutide from any seller has been through a registered trial.
Appetite regulation, blood-sugar balance and weight management are all established for semaglutide, and WellMedr claims no magnitude and names no trial, so nothing here reaches past the evidence. The same labeling problem applies: "Compounded GLP-1" is the product name, the description never says semaglutide, and the molecule appears only in the URL slug `injectable-semaglutide`. The standing caveat is unstated — STEP 1 tested the approved finished product, not a compounded preparation.3
Ozempic® (brand, cash-pay)Semaglutide · FDA-approvedClaim matches the trials
“Ozempic starting at $1,399. Contains Semaglutide. Month-to-month plan. Includes: Licensed provider review and ongoing medical oversight. Medical Weight-Care Coach for personalized guidance and accountability. Tailored dosage adjustments based on your progress and response.”
Read on the WellMedr site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. The semaglutide weight-management program. Ozempic's own approval is for type 2 diabetes; Wegovy is the weight approval of the same molecule.
For the branded products WellMedr does the thing it declines to do elsewhere: it names the molecule. "Contains Semaglutide" on Ozempic and "Contains Tirzepatide" on Zepbound are exactly the disclosures missing from its compounded line. Nothing is claimed beyond what the products are. The price is the issue: $1,399 a month for Ozempic and $1,599 for Zepbound are far above what the manufacturers charge self-paying patients through their own direct channels, and any telehealth prescriber can route a prescription there instead. One accuracy note: Ozempic is approved for type 2 diabetes, and Wegovy is the weight-management approval of the same molecule — so selling Ozempic on a weight-loss page describes an off-label use, which is lawful and common but is not the approved indication.3
Dispensing chain
Who actually fills your prescription
Read the full account
No dispensing pharmacy is named anywhere on the site. The assurances offered are two phrases, and neither describes anything checkable. "We work only with licensed U.S. providers and ACCREDITED PHARMACIES" names no accrediting body and no pharmacy. And the site-wide banner reads "FDA-REGULATED PHARMACIES", which is loose in the direction this whole category is loose: a 503A compounding pharmacy is licensed and inspected by its STATE board of pharmacy, not regulated by FDA; a 503B outsourcing facility does register with FDA, but registration is not regulation of the sort the phrase implies. WellMedr states no compounding category at all — neither 503A nor 503B appears on the site. The corporate identity is published plainly: Wellmedr LLC, info@wellmedr.com and support@wellmedr.com, with a staffed telephone line on 1-888-397-6905, Monday to Saturday 8am–8pm ET. A published phone number with stated hours is more than several of the companies we track offer. No individual clinician is named, though, and no medical group is identified. One small tell about how the site is maintained: the footer copyright reads "© wellmedr, 2025" on the product pages and "© 2026 WellMedr" on the weight-loss landing page.
Read on the WellMedr site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup is published for any product, and no pharmacy is named to ask. The site's only quality claim is the banner phrase "FDA-regulated pharmacies", which misdescribes how compounding pharmacies are overseen, and "accredited pharmacies" in the FAQ, which names no accrediting body. No compounding category is stated. That gap matters more for this catalog than for most, because WellMedr's distinctive products are COMBINATIONS — tirzepatide with NAD+ and B12 in one injection, and an oral microdose tirzepatide with NAD+, L-carnitine and B12. A multi-ingredient sterile preparation raises questions a single-molecule one does not: compatibility, stability and the potency of each component over time. Nothing on the site addresses any of them, and no document is offered. No study, trial identifier or publication is cited anywhere on the site, for any product. Its most prominent numerical claim is about the drug class rather than about WellMedr: "GLP-1 medications used by 1,000,000+ patients".
Read on the WellMedr site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Not published — WellMedr declines to answer the question and defers it to the sign-up flow
Read the full licensing claim
WellMedr publishes no state list, and it is one of the few companies to be asked the question directly in its own FAQ and decline to answer it. "What states do you serve? We are expanding rapidly — eligibility is checked during sign-up." That is an answer about process rather than coverage: a prospective patient cannot find out whether they are eligible without starting an intake. No exclusions are listed in this review because naming them would mean inventing them. Clinical oversight is described only as "licensed U.S. providers" and "U.S. licensed clinicians", with no medical group named, no individual clinician named and no license number published. The FAQ also carries a results-timeline claim on the same page: "How fast will I see results? Most members begin seeing results within the first few weeks." WellMedr does publish a real contact route — 1-888-397-6905, Monday to Saturday, 8am to 8pm ET — plus separate privacy, terms, telehealth-consent and refund-and-cancellation documents, which is a fuller set of legal pages than several of the companies we track maintain.
Read on the WellMedr site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with WellMedr
We went through WellMedr’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Press Check Eligibility, which hands you to a separate intake site.
- Enter your height and weight so it can work out your BMI.
- Enter your goal weight.
- Say whether you are male or female.
- Enter your date of birth.
- Say which conditions apply to you, or none of them.
- Say what you want out of treatment.
- Read a week-by-week story about how the medication will work for you.
- Say your primary reason for taking weight loss seriously.
- Read a pace screen that names pounds per week and a number of weeks to your goal, then say whether that pace suits you.
- Plan prices are on the get-started page before you answer anything, but the figure that governs your bill is not among them. That one waits at the checkout.
- The questions are not on wellmedr.com. Pressing Check Eligibility hands you to a separate intake site, and the form there is embedded from a third one.
- Before a clinician has seen anything, the intake tells you what will happen: your body acclimates over weeks one to four, weight loss increases through weeks four to eight, and by week nine your body has become a fat burning machine.
- It then puts a number on it. On this walk it promised 3.75 to 5 pounds a week and "about 17.33" to reach the goal weight we typed in — the sentence leaves out the unit — and asked how that pace felt, with "I want it faster" among the three answers. That screen is where this walk stopped.
- It also shows a before-and-after with a named patient down 65 pounds in six months, inside the questions rather than on a marketing page.
- WellMedr's own disclaimer says that unless otherwise noted, results shown reflect similar telehealth brands and patient experiences rather than public clinical studies.
- The home page runs a money-back guarantee in capitals: if you do not lose weight in 90 days it will refund all of your money.
WellMedr support
- Phone
- +1-888-397-6905
- support@wellmedr.com
Assessment
What holds up, and what does not
- It names the molecule plainly for its branded products — Ozempic "Contains Semaglutide", Zepbound "Contains Tirzepatide" — and for its combination products.
- Its compounded plans state "Same price regardless of dosage", so titrating upward is not supposed to change what you pay.
- "Cancel or change anytime" sits on both compounded plans, and no minimum term is stated anywhere on the site.
Show 6 more
- A staffed telephone line is published with hours — 1-888-397-6905, Monday to Saturday, 8am–8pm ET — which several of the companies we track do not offer.
- It maintains a full set of legal documents: privacy policy, terms and conditions, telehealth consent, and a refund and cancellation policy.
- It sells the approved products alongside compounded ones, so a patient can choose a manufactured drug with an NDC.
- Its core compounded GLP-1 claims are modest — appetite regulation and weight management, with no percentage quoted and no trial name-dropped.
- "Cancel or change anytime" is stated on the monthly plan.
- No FDA warning letter for WellMedr.
- "Energy & Focus+" is a GLP-1 co-formulated with NAD+ and B12, sold for "enhanced cognitive and physical output". No trial has tested that combination, and no trial of either component reports a cognitive endpoint.
- "Muscle & Energy+" stacks four unstudied choices on one molecule — a microdose, an oral route, a four-ingredient combination, and an indication that is explicitly not weight loss.
- Its core compounded products never name the molecule. "Compounded GLP-1/GIP" is tirzepatide, discoverable only from the URL slug `injectable-tirzepatide`.
Show 11 more
- Two lifetime offers that cannot both be true sit on the same page: "Lock In $200 OFF Every Month… For Life" and "New Customer Offer: $150 off for Life".
- The plan WellMedr calls a "1 Month Supply" is BILLED every 21 days — 17.33 charges a year, not 12 — so the tirzepatide plan advertised at "$99 a month" costs $2,236 a year and the semaglutide one costs $1,716.
- The page states a shipping cadence ("shipped every 4 weeks") and no billing cadence, and the two are different numbers. A reader doing the arithmetic from the fact WellMedr publishes gets $1,287 and is still wrong.
- Ozempic at $1,399 and Zepbound at $1,599 a month are far above the manufacturers' direct self-pay prices for the same products.
- Asked "What states do you serve?", its own FAQ answers "eligibility is checked during sign-up" — a process, not a coverage list.
- "FDA-regulated pharmacies" misdescribes oversight: 503A pharmacies are licensed and inspected by state boards.
- No pharmacy is named, no compounding category is stated, and no certificate of analysis or test result is published.
- Nothing addresses compatibility, stability or per-component potency for its multi-ingredient sterile injections.
- "Most members begin seeing results within the first few weeks" is a timeline claim with no source.
- Most product pages render no price at all — the Shopify variants return $0.00 — and no figure appears after the eligibility quiz either. The quiz is followed by a shipping-address form; the price exists only in the checkout.
- The footer copyright is 2025 on product pages and 2026 on the landing page.
Verdict
The bottom line
Ask WellMedr two questions about the combination products. Whether a multi-ingredient sterile injection stays stable and potent in each part — nothing on the site addresses it, no pharmacy is named and no certificate exists — and which trial tested the mixture, because tirzepatide’s large phase 3 program never measured cognition and injected NAD+ has no completed human trial at all.
Opens www.wellmedr.com. A link is not a recommendation to take anything.
A GLP-1 in the same syringe as NAD+
Most companies in this review series sell GLP-1s, and several sell NAD+. WellMedr is the first to sell them in the same injection.
Its product "Energy & Focus+", verbatim:
"Compounded Tirzepatide injection formulated with NAD+ and Vitamin B12 to help support balanced focus, sustained energy, and metabolic performance. Designed for individuals seeking enhanced cognitive and physical output through GLP-1/GIP–based therapy."
There is a second version built the same way on semaglutide. And a third, "Muscle & Energy+":
"Compounded oral microdose GLP-1/GIP* (contains Tirzepatide), formulated with NAD+, L-Carnitine, and Vitamin B12… without a primary weight-loss emphasis."
Take those apart against the evidence.
Tirzepatide has a large, genuine phase 3 program. Every trial in it measured weight, glycemia or cardiovascular outcomes. 2 None measured focus, cognition or "cognitive output".
Injected NAD+ has no completed randomized human trial supporting a restoration-of-function claim, and no registered study reports a cognitive endpoint for NAD+ by any route. 1
The combination has never been tested. A ClinicalTrials.gov search returns no registered trial of tirzepatide co-formulated or co-administered with NAD+, in any phase, for any endpoint — while the same search returns 158 records for tirzepatide on its own, so the search itself works.
So a product whose selling proposition is cognition contains one ingredient never trialled for cognition, one ingredient never trialled at all, and a pairing nobody has studied. The word "formulated" does quiet work here: it implies deliberate pharmacological design, and what is published supports none.
B12 is the one component with a real cognitive story, and it is narrow — correcting a B12 deficiency can improve cognition. That is not a reason to give B12 to someone who is not deficient, and the page never raises the distinction.
"Muscle & Energy+" is the furthest out. It stacks four unstudied choices on one molecule: a deliberately sub-therapeutic dose, an oral route for a compounded tirzepatide, a four-ingredient combination, and an indication that is explicitly not the one tirzepatide has been trialled for.
Full analysis — 5 more sectionsThe molecule is in the URL · Two lifetime offers on one page · What "$99 a month" actually costs · Who makes it, and where you can get it · What this means if you are buying
The molecule is in the URL
WellMedr's core compounded products are called:
- "Compounded GLP-1" — handle `injectable-semaglutide`
- "Compounded GLP-1/GIP" — handle `injectable-tirzepatide`
- "Compounded Oral GLP-1" — handle `oral-semaglutide`
- "Compounded Oral GLP-1/GIP" — handle `oral-tirzepatide`
The titles name a receptor class. The descriptions never name the molecule either. The only place a buyer can learn what they are being prescribed is the URL slug.
What makes this a choice rather than an oversight is that WellMedr names the molecule everywhere else. Ozempic's description says "Contains Semaglutide". Zepbound's says "Contains Tirzepatide". Both "Energy & Focus+" products name theirs, and "Muscle & Energy+" says "(contains Tirzepatide)".
Only the core compounded line is anonymous.
Two lifetime offers on one page
At the top of WellMedr's weight-loss page:
"🎉 Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life."
Further down the same page:
"New Customer Offer: $150 off for Life. Welcome to Wellmedr. Join today and lock in $150 off for life — no long term commitments."
$200 off for life and $150 off for life cannot both be the offer. Neither carries a date or a condition that reconciles them.
What "$99 a month" actually costs
The headline is on the page and the real number is not:
"⭐ Recommended for most patients — Monthly Plan Starting At $99 a month — Shipped every 4 weeks — ✔ Tirzepatide shipped every 4 weeks ✔ Dosing adjusted as your body responds ✔ Cancel or change anytime"
The tempting move is to take "shipped every 4 weeks" and multiply: a 52-week year holds 13 four-week cycles, so $99 a month must be about $1,287. That is wrong, and this review published it until August 11, 2026.
A shipping cadence is not a billing cadence. WellMedr's checkout loads each plan by ID and asks its payment processor what the plan costs, and the plans it calls a "1 Month Supply" are set to charge every 21 days — three weeks, not four. That is 17.33 charges a year. Compounded tirzepatide is $129 every 21 days, or $2,236 a year; compounded semaglutide is $99 every 21 days, or $1,716.
The prepay plans are short in the same direction — the "3-Month" bills every 80 days, the "6-Month" every 170, the "12-Month" every 350 — at $428, $838 and $1,538 for tirzepatide and $278, $538 and $1,058 for semaglutide. The cheapest 30 days of WellMedr semaglutide anyone can actually buy costs $91, against an advertised $59.
The branded products are a different matter: Ozempic at $1,399 a month and Zepbound at $1,599. Novo Nordisk and Eli Lilly both sell those exact products to self-paying patients through their own direct channels for a fraction of that, and any telehealth prescriber can send a prescription there.
(One accuracy note WellMedr does not make: Ozempic is approved for type 2 diabetes. Wegovy is the weight-management approval of the same molecule. Selling Ozempic on a weight-loss page is off-label — lawful and routine, but not the approved indication.)
Who makes it, and where you can get it
Neither is answered.
No dispensing pharmacy is named. The site offers two phrases instead: "accredited pharmacies", which names no accrediting body, and a banner reading "FDA-regulated pharmacies", which misdescribes how compounding is overseen — a 503A pharmacy is licensed and inspected by its state board, not regulated by FDA. WellMedr states no compounding category at all.
That gap matters more here than usual. WellMedr's distinctive products are multi-ingredient sterile injections, and mixing tirzepatide with NAD+ and B12 raises questions a single-molecule preparation does not: compatibility, stability, and whether each component is still at its stated potency by the end of a vial. Nothing on the site addresses any of it, and no certificate of analysis, lot number or test result is published for anything.
On coverage, WellMedr's own FAQ asks the question and declines it:
"What states do you serve? We are expanding rapidly — eligibility is checked during sign-up."
That is a description of a process, not an answer. A prospective patient cannot find out whether they are eligible without starting an intake.
To its credit, WellMedr publishes a real telephone line with hours — 1-888-397-6905, Monday to Saturday, 8am–8pm ET — plus privacy, terms, telehealth-consent and refund documents, which is a fuller set than several companies here maintain.
What this means if you are buying
For a plain compounded GLP-1, WellMedr is unremarkable in the good sense: modest claims, a published starting price, a phone number. Check the URL to confirm which molecule you are getting, and budget thirteen charges a year rather than twelve.
Do not buy Ozempic or Zepbound here at $1,399 and $1,599 without first checking the manufacturers' own direct-to-patient prices.
And treat "Energy & Focus+" and "Muscle & Energy+" as what they are: combinations assembled for a purpose neither active ingredient has been trialled for. If you want a GLP-1, the evidence for that is strong and it does not require NAD+ in the syringe. If you want the cognitive benefit the name promises, there is no trial behind it — and a multi-ingredient sterile injection with no published stability or potency data is the least verifiable way to pursue it.
Questions
Frequently asked questions
Is there evidence for mixing a GLP-1 with NAD+?
None. As of 10 August 2026, a ClinicalTrials.gov search returns no registered trial of tirzepatide or semaglutide co-formulated or co-administered with NAD+, in any phase, for any endpoint — while the same search returns 158 records for tirzepatide alone, so the search itself works. Each component fails separately too: tirzepatide's phase 3 program measured weight, glycemia and cardiovascular outcomes and never cognition, and injected NAD+ has no completed randomized human trial at all and none reporting a cognitive endpoint by any route. WellMedr's "Energy & Focus+" is sold for "enhanced cognitive and physical output", which is an intention rather than a demonstrated effect. Vitamin B12, the third ingredient, has a real but narrow cognitive story — correcting a deficiency can help — which is not a reason to give it to someone who is not deficient.
Which drug is WellMedr's "Compounded GLP-1/GIP"?
Tirzepatide — and you can only learn that from the URL. WellMedr's core compounded products are titled by receptor class ("Compounded GLP-1", "Compounded GLP-1/GIP", and oral versions of each), and their descriptions never name the molecule. The product handles do: injectable-semaglutide, injectable-tirzepatide, oral-semaglutide, oral-tirzepatide. What makes this a choice rather than an oversight is that WellMedr names the molecule everywhere else on the site — Ozempic "Contains Semaglutide", Zepbound "Contains Tirzepatide", and both combination products name theirs. Only the core compounded line is anonymous. Check the address bar before you buy.
What does WellMedr actually cost per year?
Considerably more than the monthly figure suggests, and more than the page gives you the means to work out. Its weight-loss page advertises a "Monthly Plan Starting At $99 a month" and states that it is "shipped every 4 weeks" — but that is the shipping cadence, and the BILLING cadence is 21 days. Its checkout charges $129 every 21 days for compounded tirzepatide and $99 every 21 days for compounded semaglutide, which is 17.33 charges a year: $2,236 and $1,716 respectively. A reader who takes the four-week figure at face value and multiplies by 13 arrives at $1,287 and is still short by nearly a thousand dollars. Two other things to watch: the branded products are priced far above the manufacturers' own direct self-pay channels, at $1,399 a month for Ozempic and $1,599 for Zepbound; and two incompatible lifetime discounts appear on the same page, "$200 OFF Every Month… For Life" at the top and "$150 off for Life" further down.
Does WellMedr say which pharmacy makes its medication?
No, and its two quality phrases do not survive checking. "Accredited pharmacies" names no accrediting body, and the site-wide banner "FDA-regulated pharmacies" misdescribes the oversight: a 503A compounding pharmacy is licensed and inspected by its state board, not regulated by FDA. WellMedr states no compounding category anywhere, names no pharmacy, and publishes no certificate of analysis, lot number, potency or sterility result. That gap is more consequential here than at most of the companies we track, because WellMedr's distinctive products are multi-ingredient sterile injections — tirzepatide with NAD+ and B12 in one syringe — which raise compatibility, stability and per-component potency questions that a single-molecule preparation does not. Nothing on the site addresses them.
Does WellMedr serve my state?
It will not say. Its own FAQ asks the question and answers with a process: "What states do you serve? We are expanding rapidly — eligibility is checked during sign-up." No state list, map or exclusion notice appears anywhere on the site, so a prospective patient cannot establish eligibility without starting an intake. No medical group is named and no individual clinician or license number is published; clinical oversight appears only as "licensed U.S. providers". WellMedr does publish a staffed telephone line with hours — 1-888-397-6905, Monday to Saturday, 8am to 8pm ET — which is the one route available for asking before you commit.
Glossary
Key terms
Show definitions
- Co-formulation
- Combining two or more active ingredients in a single preparation. It raises questions a single-ingredient product does not — chemical compatibility, stability over the vial's life, and whether each component holds its stated potency — none of which WellMedr addresses.
- "FDA-regulated pharmacy"
- A misdescription. 503A compounding pharmacies are licensed and inspected by state boards of pharmacy. 503B outsourcing facilities register with FDA and are subject to inspection, but registration is not the blanket regulation the phrase implies.
- Four-week cycle
- A 28-day shipping and billing interval. A 52-week year holds 13 of them, not 12, so a "monthly" price billed this way costs about 8% more per year than it appears to.
Compare
Others selling what WellMedr sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off WellMedr's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected NAD+ in humans, and for tirzepatide or semaglutide combined with NAD+: no completed randomised trial supporting a restoration-of-function claim, no registered study reporting a cognitive endpoint for NAD+ by any route, and no registered trial of a GLP-1 co-formulated or co-administered with NAD+ in any phase. In the same pass, a search for tirzepatide alone returned 158 records naming it as an intervention, confirming the searches work. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.